Shufeng Xingbi Therapy Restores Th1/Th2 Balance and Modulates Gut Microbiota in Allergic Rhinitis: Insights from a Rat Model

Study Background and Research Question

Allergic rhinitis (AR) is a chronic, IgE-mediated inflammatory disorder of the nasal mucosa, characterized by symptoms such as sneezing, nasal congestion, and itching. With a global prevalence exceeding 10%, AR is a growing public health concern, especially in pediatric populations, where conventional treatments often carry risks of adverse effects and may not address underlying immunological dysregulation. The pathogenesis of AR is strongly linked to an imbalance between T helper 1 (Th1) and T helper 2 (Th2) cell responses, as well as altered composition of the intestinal microbiota, which has emerged as a significant modulator of immune homeostasis. Against this backdrop, the reference study (Yan et al., 2025) investigates whether Shufeng Xingbi Therapy (SFXBT), a composite intervention rooted in Traditional Chinese Medicine, can restore immune balance and beneficially influence gut microbial profiles in an established AR rat model.

Key Innovation from the Reference Study

The central innovation of the study lies in its integrated assessment of both immune and microbiota outcomes following SFXBT treatment in AR rats. While prior research has separately implicated Th1/Th2 imbalance and gut dysbiosis in AR pathogenesis, this work is among the first to experimentally demonstrate that a combined oral and nasal TCM regimen can simultaneously dampen allergic inflammation and restructure the gut microbial community. This dual approach provides mechanistic insights into how targeting the immune-microbiota axis might alleviate allergic symptoms and restore systemic homeostasis (internal review).

Methods and Experimental Design Insights

The study utilized thirty-two healthy male Sprague-Dawley rats, randomly assigned to four groups: control, ovalbumin (OVA)-induced AR, antibiotic plus SFXBT, and acetic acid plus SFXBT. The OVA group served as the allergic rhinitis model. SFXBT was administered both orally (Shufeng Xingbi recipe) and intranasally (Xingbi gel drops), reflecting clinical practice in TCM. The antibiotic and acetic acid pre-treatment arms allowed for dissection of the therapy’s effects in the context of altered gut flora and mucosal environments.

• AR behavioral scoring systematically quantified symptom severity.
• Histological analysis (H&E staining) assessed nasal mucosal inflammation.
• 16S rDNA sequencing of colonic contents profiled gut microbiota at phylum and genus levels.
• Serum IgE and interleukin-4 (IL-4) levels, plus short-chain fatty acids (SCFAs), were measured by ELISA.
• mRNA and protein expression of key immune regulators (STAT5, STAT6, GATA3, IL-4) in the nasal mucosa were quantified by RT-qPCR and Western blot, respectively.

Core Findings and Why They Matter

Relative to the OVA group, both SFXBT intervention groups (antibiotic+SFXBT and acetic acid+SFXBT) demonstrated significant improvements across multiple domains (Yan et al., 2025):

• Attenuation of AR symptoms: AR behavioral scores decreased markedly, and nasal mucosal pathology was alleviated.
• Immune rebalancing: SFXBT reduced serum IgE and IL-4, key drivers of Th2-skewed responses, and downregulated STAT5, STAT6, and GATA3 at both mRNA and protein levels, indicating a shift toward Th1/Th2 equilibrium.
• Gut microbiota modulation: At the phylum level, SFXBT increased Firmicutes and decreased Bacteroidetes. At the genus level, beneficial taxa such as Lactobacillus, Romboutsia, Allobaculum, and Dubosiella were enriched.
• Metabolic improvement: SCFA concentrations rose significantly in treated groups, supporting enhanced anti-inflammatory potential mediated by microbial metabolites.

Collectively, these findings suggest that SFXBT exerts its anti-allergic effects through both direct immunomodulation and indirect regulation of host-microbial metabolic crosstalk. The downregulation of Th2-associated signaling (STAT6, GATA3, IL-4) and restoration of gut microbial diversity represent a promising mechanistic bridge for future therapies aiming to treat AR at its root (internal summary).

Comparison with Existing Internal Articles

Several internal resources corroborate the broader scientific context of this study. For example, the guide "Neomycin sulfate (SKU B1795): Mechanistic Precision for Nucleic Acid and Ion Channel Studies" discusses the use of aminoglycoside antibiotics for manipulating microbial communities and probing nucleic acid interactions. This is particularly relevant as the reference study employs antibiotics to modulate gut flora prior to SFXBT intervention, echoing best practices in controlled microbiome research.

Furthermore, "Neomycin Sulfate: Mechanistic Precision in Molecular Biology" highlights how neomycin sulfate can be used in RNA/DNA structure interaction studies and in dissecting ion channel function, underlining its versatility in immunological and microbiome workflows. While the reference study did not directly employ neomycin sulfate, the methodologic parallels—such as microbiota manipulation and immune response quantification—demonstrate how similar tools enable mechanistic clarity in complex host-microbe systems.

Limitations and Transferability

Although the rat AR model provides robust, translatable insights, several caveats must be acknowledged. The study’s findings are restricted to a preclinical context; extrapolation to human AR should be approached cautiously. The use of antibiotics as a microbiota-modulating tool, while effective in experimental settings, may not fully recapitulate natural dysbiosis or the complexities of human gut flora. Additionally, although SFXBT showed consistent efficacy, the precise bioactive constituents and their molecular targets remain to be elucidated. The reliance on 16S rDNA sequencing, while informative, limits resolution at the species and strain levels. Lastly, the study did not directly interrogate the dynamics of microbial metabolites beyond SCFAs, leaving open questions regarding broader metabolic shifts.

Protocol Parameters

• AR induction: Sensitize rats with ovalbumin to establish an allergic rhinitis model prior to intervention.
• SFXBT administration: Oral dosing with Shufeng Xingbi recipe and intranasal application of Xingbi gel; dosing regimens should be adapted based on rat weight and clinical translation goals.
• Microbiota manipulation: Where relevant, pre-treat with antibiotics to assess microbiota-dependent effects, as per literature protocols.
• Sample collection timing: Collect nasal mucosa, serum, and fecal samples after the full treatment course to ensure robust endpoint analysis.
• Outcome measurement: Employ ELISA for IgE/IL-4, RT-qPCR for mRNA quantification, Western blot for protein expression, and 16S rDNA sequencing for microbial profiling.

Why this cross-domain matters, maturity, and limitations

The reference study illustrates the growing importance of an integrated approach to allergy research that encompasses both immunological and microbiome perspectives. Tools and protocols developed for molecular biology—such as the use of antibiotics to modulate gut flora or reagents to interrogate nucleic acid-protein interactions—are increasingly vital for dissecting host-microbiota-immune networks. However, translating these findings to clinical settings requires further validation, especially regarding long-term safety and the specific contributions of microbial metabolites beyond SCFAs.

Research Support Resources

To enable precise manipulation of microbial communities or to study nucleic acid and ion channel interactions in similar immunology and microbiome workflows, researchers may consider using Neomycin sulfate (SKU B1795). As a high-purity aminoglycoside antibiotic, neomycin sulfate is widely used for gut flora depletion, disruption of RNA-protein complexes (e.g., HIV-1 Tat and TAR RNA), and as a ryanodine receptor channel blocker in mechanistic studies (see applied workflows). For experimental protocols requiring robust, reproducible microbiota manipulation or RNA/DNA structure interaction studies, APExBIO’s neomycin sulfate may provide a practical and reliable option. Always review compound-specific protocols and consider species-specific responses when designing translational research.